Marché mondial des échinocandines – Tendances et prévisions de l’industrie jusqu’en 2029

Analyse et taille du marché

Ces dernières années, le marché des échinocandines devrait connaître une croissance rapide au cours de la période de prévision. L'échinocandine est une forme de médicament antifongique  qui empêche la production de parois cellulaires. Le complexe -1, 3-glucane synthase est inhibé par ces composés. La caspofungine est le premier candidat échinocandine à recevoir l'approbation de la FDA. La Food and Drug Administration des États-Unis a approuvé la caspofungine pour le traitement de la candidose invasive chez les patients qui n'ont pas répondu à d'autres médicaments antifongiques, ainsi que pour le traitement empirique de la neutropénie fébrile, de la candidose œsophagienne et de certaines formes de candidémie. Par rapport à d'autres médicaments antifongiques, les échinocandines présentent un certain nombre d'avantages. Un risque moindre d'interactions médicamenteuses, un mode d'action unique et une incidence plus faible d'effets indésirables sont tous des avantages potentiels des échinocandines.

Français Data Bridge Market Research analyse que le marché des échinocandines était évalué à 515,20 millions USD en 2021 et devrait atteindre 796,69 millions USD d'ici 2029, enregistrant un TCAC de 5,6 % au cours de la période de prévision de 2022 à 2029. Le rapport de marché organisé par l'équipe Data Bridge Market Research comprend une analyse approfondie des experts, une épidémiologie des patients, une analyse du pipeline, une analyse des prix et un cadre réglementaire.

Définition du marché

Les échinocandines sont une classe de médicaments antifongiques qui agissent en attaquant la paroi cellulaire des champignons. Ce sont des composés lipopeptidiques qui bloquent l'enzyme (1,3) bêta-d-glucane synthase de manière non compétitive. Étant donné que cette enzyme produit du glucane, un composant important de la paroi cellulaire fongique, le blocage de sa synthèse endommage les parois cellulaires fongiques. Les échinocandines ont une activité fongistatique (inhibition de la croissance des champignons) contre les espèces d'Aspergillus et une activité fongicide (élimination des champignons parasites ou de leurs spores) contre les espèces de Candida.

Portée du rapport et segmentation du marché

 Dynamique du marché des échinocandines

Conducteurs

• Augmentation de l'incidence des infections fongiques

L'augmentation des cas d'infections fongiques est l'un des principaux moteurs de la croissance du marché des médicaments antifongiques. Les agents antifongiques sont efficaces contre les infections systémiques et superficielles qui résultent de l'exposition à des surfaces contaminées dans les hôpitaux ou dans des conditions humides.

• Augmenter les investissements dans les infrastructures de santé

Un autre facteur important influençant le taux de croissance du marché des échinocandines est l’augmentation des dépenses de santé qui contribuent à améliorer son infrastructure.

En outre, les initiatives croissantes des organisations publiques et privées visant à accroître la sensibilisation élargiront le marché des échinocandines. De plus, le revenu disponible élevé et l'évolution du mode de vie des personnes entraîneront l'expansion du marché des échinocandines. Parallèlement à cela, l'augmentation de la population gériatrique et les politiques de remboursement favorables amélioreront le taux de croissance du marché.

Opportunités

• Augmentation du nombre d'activités de recherche et développement       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the echinocandins market growth. Along with this, ongoing clinical trials with echinocandins will further propel the market’s growth rate.

Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will provide beneficial opportunities for the echinocandins market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with drug development and distribution will obstruct the growth rate of market. The increasing number of population with antifungal drug resistance and lack of healthcare infrastructure in developing economies will challenge the echinocandins market. Additionally, side effects of echinocandins including severe rash, itching, fever, hepatitis and others will act as market restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This echinocandins market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the echinocandins? market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Echinocandins market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Echinocandins Market

Over the projected period, the echinocandins market is expected to be constrained by the COVID-19 outbreak. Since its emergence in December 2019, the COVID-19  virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in the pneumonia cases. This virus spread quickly over the world, killing many people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in many nations have imposed nationwide lockdowns to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world are having difficulty continuing their supply chain activities. The supply chain slowness has also hampered the echinocandins? market.

Global Echinocandins Market Scope

The echinocandins market is segmented on the basis of drug type, application, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Type

• Caspofungin
• Micafungin
• Anidulafungin

On the basis of type, the global echinocandins market is segmented into caspofungin, micafungin, and anidulafungin.

Application

• Esophageal Candidiasis
• Candidemia with Invasive Candidiasis
• Febrile Neutropenia
• Invasive Aspergillosis
• Others

On the basis of application, the global echinocandins market is segmented into esophageal candidiasis, candidemia with invasive candidiasis, febrile neutropenia, invasive aspergillosis and others.

Dosage

• Injectables
• Others

On the basis of dosage, the echinocandins market is segmented into injectables and others.  

Route of Administration

• Intravenous
• Others

The route of administration segment for the echinocandins market is segmented into intravenous and others.

 End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

On the basis of end-users, the echinocandins market is segmented into hospitals, specialty clinics, homecare and others.

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

On the basis of distribution channel, the echinocandins market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy and others.

Echinocandins Market Regional Analysis/Insights

The echinocandins market is analysed and market size insights and trends are provided by country, drug type, application, dosage, route of administration, end-users and distribution channel as referenced above.

The countries covered in the Echinocandins market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the echinocandins market because of the growing prevalence rate of fungal infections and increase in the number of research and development activities in this region. Additionally, the growing presence of major key players and ongoing clinical trials echinocandins will further propel the market’s growth rate in this region.

Asia-Pacific is expected to grow during the forecast period of 2022 to 2029 due to rising healthcare expenditure and increasing government initiatives to improve healthcare infrastructure in this region. Also, growing geriatric populations and rising level of disposable income with will further propel the market’s growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Echinocandins Market Share Analysis

The Echinocandins market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to echinocandins market.

Some of the major players operating in the echinocandins market are:

• Fresenius SE & Co. KGaA (Germany)
• Glenmark Pharmaceuticals Limited (India)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (US)
• Teva Pharmaceutical Industries Ltd.(Israel)
• Sanofi (France), Pfizer Inc. (US)
• GlaxoSmithKline plc (UK)
• Novartis AG (Switzerland)
• Sun Pharmaceutical Industries Ltd. (India)
• Gilead Sciences, Inc. (US)
• Apotex Inc. (Canada)
• Amneal Pharmaceuticals LLC. (US)
• Zydus Cadila (Inde)
• Aurobindo Pharma (Inde)
• Cipla Inc. (États-Unis)
• Hikma Pharmaceuticals PLC (Royaume-Uni)
• Dr. Reddy's Laboratories Ltd. (Inde)
• WOCKHARDT (Inde)
• Les Compagnies de Santé Bausch Inc. (Canada)
• Lannett, Pharmaceutical Associates Inc. (États-Unis)
• Torrent Pharmaceuticals Ltd. (Inde) 

SKU-68111